Composition for Treating Prostate Cancer

Patent metadata

Field	Value
Publication number	US-2016375091-A1
Application number	US-201415105289-A
Country	US
Kind code	A1
Filing date	Dec 17, 2014
Priority date	Dec 17, 2013
Publication date	Dec 29, 2016
Grant date	—

Abstract

The present invention relates to a composition for treating prostate cancer and, more specifically, to a composition for treating prostate cancer, which contains a peptide derived from telomerase and is effective in inhibiting growth and metastasis of prostate cancer cells. In addition, the present invention provides a composition and method for treating prostate cancer, wherein, when prostate cancer is treated, docetaxel and the peptide derived from telomerase are co-administered, thereby having a synergetic therapeutic effect compared with administration alone. Particularly, the present invention provides a treatment method useful for patients who do not have a sufficient anticancer effect merely through administration of docetaxel alone and patients who have hormone resistance.

First claim

1 - 15 . (canceled)

16 . A method of treating prostate cancer comprising administering to a subject in need thereof the isolated peptide of SEQ ID NO: 1.

17 . The method according to claim 16 , wherein the prostate cancer has hormone tolerance.

18 . The method according to claim 16 , wherein the peptide is co-administered with an anti-cancer drug.

19 . The method according to claim 18 , wherein the anti-cancer drug is doetaxel or leuprolide acetate.

20 . The method according to claim 16 , wherein the peptide is co-administered with an adjuvant.

21 . The method according to claim 20 , wherein the adjuvant is macrophage colony-stimulating factor (GM-CSF).

22 . The method according to claim 19 , wherein the cytokine adjuvant macrophage colony-stimulating factor (GM-CSF) is further co-administered.

23 . The method according to claim 16 , wherein the patient has at least one of eotaxin and MIP 1 a at a serum concentration of at least 10% as high as the average concentration of eotaxin and MIP 1 a in all patients including the patient.

24 . The method according to claim 16 , wherein the peptide is administered at a daily dose of 0.1 ng/kg to 10 mg/kg.

25 . A method of treating prostate cancer comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO:1.

26 . The method according to claim 26 , wherein the prostate cancer has hormone tolerance.

27 . The method according to claim 26 , wherein the composition is co-administered with an anti-cancer drug.

28 . The method according to claim 27 , wherein the anti-cancer drug is doetaxel or leuprolide acetate.

29 . The method according to claim 26 , wherein the composition is co-administered with an adjuvant.

30 . The method according to claim 28 , wherein the adjuvant macrophage colony-stimulating factor (GM-CSF) is further co-administered.

31 . The method according to claim 25 , wherein the patient has at least one of eotaxin and MIP1α at a serum concentration of at least 10% as high as the average concentration of eotaxin and MIP1α in all patients including the patient.

32 . The method according to claim 25 , wherein the composition is administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous routes.

33 . The method of claim 25 , wherein the composition comprises 0.01 g/L to 1 kg/L of the isolated peptide.

34 . The method of claim 25 , wherein the peptide is administered at a daily dose of 0.1 ng/kg to 10 mg/kg.

35 . A composition for treating prostate cancer comprising the isolated peptide of SEQ ID NO: 1 and at least one selected from the group consisting of a chemotherapeutic agent and an adjuvant.

Assignees

• Kim Sang Jae
• Gemvax & Kael Co Ltd

Inventors

• Kim Sang Jae

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title